References
- Newman DJ, Thakkar H, Edwards RG, Wilkie M, White T, Grubb AO, Price CP. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine.Kidney Int 1995;47:312–8.
- Grubb AO, Löfberg H. Human -trace, a basic microprotein: Amino acid sequence and presence in the adenohypophysis. Proc. Nati. Acad. Sci. USA 1982;79:3024–7.
- Abrahamson M, Olafsson I, Palsdottir A, Ulvsback M, Lundwall A, Jens son O, Grubb A.. Struc-ture and expression of the human cystatin C gene. Biochem. I 1990;268:287–94.
- Jacobsson B, Lignelid H, Bergerheim US. Transthyretin and cystatin C are catabolized in proxi-mal tubular epithelial cells and the proteins are not useful as markers for renal cell carcinomas. Histopathology 1995;26:559–64.
- Grubb AO. Cystatin C-properties and use as diagnostic marker. Adv Clin Chem 2000;35:63–99.
- Laterza OF, Price CP, Scott MG. Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem 2002;48: 5;63–99.
- Data from an unpublished patient study carried out at Uppsala University Hospital and Karlstad Hospital in Sweden using Gentian cystatin C immunoassay. March 2006.
- Larsson A, Maim J, Grubb A, Hansson LO. Calculation of glomerular filtration rate expressed in mL/min from plasma Cystatin C values in mg/L. Scand. I Lab. Invest. 2004;64,25–30.
- Stabuc B, Vrhovec L Stabuc-Silih M, Cizej TE. Improved prediction of decreased creatinine clearance by serum cystatin C: use in cancer patients before and during chemotherapy. Clin Chem 2000;46:193–7.
- Bricon T, Thervet E, Froissart M, Benlakehal M, Bousquet B, Legendre C, et al. Plasma cystatin C is superior to 24-h creatinine clearance and plasma creatinine for estimation of glomerular filtration rate 3 months after kidney transplantation. Clin Chem 2000;46:1206–7.
- Harmoinen APT, Kouri TT, Wirta OR, Lehtimki TJ, Rantalaiko V, Turjanmaa VMH, et al. Evalu-ation of plasma cystatin C as a marker for glomerular filtration rate in patients with type 2 diabe-tes. Clin Nephrol 1 999;52:363–70.
- Schade R, Hlinak A, Marburger A, Henklein P, Morgenstern R, Blankenstein Petal. Advantages of using egg yolk antibodies in the life sciences: the results of five studies. ATLA 1997;25:555–586.
- Larsson A, Balow RM, Lindahl TL, Forsberg PO. Chicken antibodies: taking advantage of evolu-tion-a review. Poultry Science 1993;72:1807–1812.
- Carlander D, Larsson A. Avian antibodies can eliminate interference due to complement activa-tion in ELISA. Ups J Med Sci. 2001;106:189–95.
- NCCLS EP7-A. Interference Testing in Clinical Chemistry; Approved Guideline. Vol 22, No 27.
- Sonntag O, Scholer A. Drug interference in clinical chemistry: recommendation of drugs and their concentrations to be used in drug interference studies. Ann Clin Biochem 2001;38:376–385.
- Burtis CA, Ashwood ER, Bruns DE.TIETZ Textbook of CLINICAL CHEMISTRY and MOLECU-LAR DIAGNOSTICS, fourth edt, Elsevier Saunders.
- NCCLS EP6-A. Evaluation of the Linearity of Quantitative Measurement Procedures: A Statisti-cal Approach; Ap-proved Guideline. Vol 23, No 16.
- NCCLS EP5-A. Evaluation of Precision Performance of Clinical Chemistry Devices; Approved Guideline Vo119, No 2.
- NCCLS EP17-A. Protocols for Determination of Limits of Detection and Limits of Quantitation; Approved Guideline. Vol 24, No 34.
- NCCLS EP9-A2. Method Comparison and Bias Estimation Using Patient samples; Approved Guideline-Second Edition. Vol 22, No 19.
- NCCLS EP10-A2. Preliminary Evaluation of Quantitative Clinical Laboratory Methods; Ap-proved Guideline-Second edition. Vol 22, No 29.
- European Standard EN 13640. Stability testing of in vitro diagnostic reagents. 2002.
- NCCLS C28-A. How to define and Determine Reference Intervals in the Clinical Laboratory; Approved Guideline-Second Edition. Vo115,No 4.
- Finney H, Newman DJ, Gruber W, Merle P, Price CP. Initial evaluation of cystatin C measure-ment by particleenhanced immunonephelometry on the Behring nephelometer systems (BNA, BN II). Clin Chem 1997;43:6:1016–1022.